[Lung cancer in Eastern Morocco: where do we stand?]
Cancer du poumon au Maroc Oriental: où en sommes-nous?
Adenocarcinoma
/ epidemiology
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Carcinoma, Small Cell
/ epidemiology
Carcinoma, Squamous Cell
/ epidemiology
Female
Humans
Lung Neoplasms
/ epidemiology
Male
Middle Aged
Morocco
/ epidemiology
Neoplasm Staging
Retrospective Studies
Risk Factors
Smoking
/ epidemiology
Young Adult
Eastern Morocco
Lung cancer
cannabis
epidemiology
molecular test
smoking
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
07
2019
accepted:
29
10
2019
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Lung cancer is the most common cancer in men living Eastern Morocco. We here present the first report on the clinical, pathological and therapeutic features of lung cancer in Eastern Morocco. We conducted a retrospective study of 738 patients diagnosed with lung cancer at the Hassan II, Oncology Center between October 2005 and December 2014. Among the cases studied, 671 patients were men and 67 women; 95.01% of men and 1.54% of women were smokers. The average age of patients was 59.1 ± 11.9 years. Most patients (97%) were diagnosed at advanced stage disease. Only 4 out of 227 patients with advanced adenocarcinoma underwent molecular test. In addition, no patient in our series received targeted therapy. In this series, 20.46% of patients had less than 50 years. Compared to patients aged 50 years and older, cannabis consumption was higher (p<0.001) in patients less than 50 years and as well as a higher rate of adenocarcinoma (p<0.01). By contrast, in these patients, tobacco consumption was lower (p<0.001) as well as the rate of squamous cell carcinoma (p<0.01) and small cell cancer (p<0.05). Unlike Western countries, in Eastern Morocco lung cancer is diagnosed late, affects younger people and access to molecular tests is still very limited. These results justify the need to implement effective programs against lung cancer as well as to facilitate access to molecular tests and new therapeutic tools in Eastern Morocco.
Identifiants
pubmed: 32153717
doi: 10.11604/pamj.2019.34.177.19934
pii: PAMJ-34-177
pmc: PMC7046119
doi:
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
177Informations de copyright
© Mohammed Bellaoui et al.
Déclaration de conflit d'intérêts
Les auteurs ne déclarent aucun conflit d'intérêts.
Références
Asian Pac J Cancer Prev. 2013;14(10):6181-4
pubmed: 24289645
Rev Mal Respir. 2013 Sep;30(7):537-48
pubmed: 24034458
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Pan Afr Med J. 2013 Sep 29;16:31
pubmed: 24570792
Pathologe. 2014 Nov;35 Suppl 2:188
pubmed: 25394966
Asian Pac J Cancer Prev. 2013;14(3):1989-93
pubmed: 23679305
Rev Epidemiol Sante Publique. 2016 Dec;64(6):391-395
pubmed: 27793413
J Thorac Oncol. 2008 Aug;3(8):819-31
pubmed: 18670299
Mali Med. 2006;21(1):4-7
pubmed: 17390521
Crit Rev Oncol Hematol. 2013 Dec;88(3):494-503
pubmed: 23921082
Rev Mal Respir. 2011 Oct;28(8):1048-58
pubmed: 22099410
Ann Pathol. 2016 Jan;36(1):73-9
pubmed: 26778816
J Med Invest. 2010 Aug;57(3-4):326-33
pubmed: 20847534
Asian Pac J Cancer Prev. 2011;12(9):2305-9
pubmed: 22296375
Asian Pac J Cancer Prev. 2013;14(12):7277-81
pubmed: 24460288
Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S10-5
pubmed: 18235388
Asian Pac J Cancer Prev. 2012;13(9):4639-43
pubmed: 23167394
Pan Afr Med J. 2015 Nov 20;22:271
pubmed: 26958134
Pneumonol Alergol Pol. 2016;84(3):186-92
pubmed: 27238182
Rev Mal Respir. 2002 Dec;19(6):727-34
pubmed: 12524492
Rev Mal Respir. 2006 Feb;23(1 Pt 1):43-8
pubmed: 16604025
Clin Chest Med. 2011 Dec;32(4):605-44
pubmed: 22054876
Ecancermedicalscience. 2013 Aug 08;7:338
pubmed: 23940493
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
PLoS One. 2016 Mar 21;11(3):e0151987
pubmed: 26998751
BMC Cancer. 2017 Aug 29;17(1):587
pubmed: 28851324